What is Assembly Biosciences's G&A?

Assembly Biosciences (ASMB) reported G&A of $4.68M in Q1 2026.

How has Assembly Biosciences's G&A changed year-over-year?

Assembly Biosciences's G&A increased by 3.9% year-over-year, from $4.51M to $4.68M.

What is the long-term trend for Assembly Biosciences's G&A?

Over 4 years (2021 to 2025), Assembly Biosciences's G&A has grown at a -9.1% compound annual growth rate (CAGR), from $28.78M to $19.61M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Assembly Biosciences ASMB G&A

G&A at other companies

Avalo TherapeuticsAVTX

$6.85M+23.6%

Arbutus Biopharma CorporationABUS

$5.89M+1.0%

Apogee Therapeutics, Inc.APGE

$21.95M+31.4%

Aurinia PharmaceuticalsAUPH

$22.03M+8.3%

Other financials

Income statement

See full

Revenue$8.2M-12.8%

Operating income-$11.4M-14.4%

Net income-$9.1M-3.0%

EPS (diluted)-$0.54+53.8%

Balance sheet

See full

Cash & equivalents$31.1M+32.9%

Total debt$2.5M-17.5%

Total equity$198.6M+632%

Total assets$235.5M+138%

Cash flow

See full

Operating cash flow-$22.1M+5.7%

CapEx$19.0K—

Free cash flow-$22.1M+5.6%

Valuation

See full

Market cap$480.77M+262%

Enterprise value$452.14M+302%

P/S6.8×+2.6×

Profitability

See full

Operating margin-116.8%-26.1pp

Net margin-103.6%-22.7pp

FCF margin-150%-231pp

Returns & leverage

See full

Return on equity-36.9%-15.1pp

Debt / equity0×-0.1×

Current ratio6.6×+4.6×

Where this comes from

Reported directly by Assembly Biosciences in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Assembly Biosciences's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Assembly Biosciences's G&A?: Assembly Biosciences (ASMB) reported G&A of $4.68M in Q1 2026.
How has Assembly Biosciences's G&A changed year-over-year?: Assembly Biosciences's G&A increased by 3.9% year-over-year, from $4.51M to $4.68M.
What is the long-term trend for Assembly Biosciences's G&A?: Over 4 years (2021 to 2025), Assembly Biosciences's G&A has grown at a -9.1% compound annual growth rate (CAGR), from $28.78M to $19.61M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.